Table 1.

Endpoint changes in secondary efficacy measures.

Efficacy measure	RLAI (n = 326)	Quetiapine	p-value (RLAI versus quetiapine)
MADRS scores
Total	−2.85±8.65***	−0.88±9.22*	0.004
Apparent sadness	−0.51±1.31***	−0.22±1.29*	0.003
Reported sadness	−0.37±1.36***	−0.23±1.32**	0.177
CGI-C	0.03±1.23***	−0.39±1.31#	<0.0001

Data represent mean ± standard deviation.

Decreases represent symptomatic improvement in MADRS scores.

CGI-C scores range from 3 (very much improved) to −3 (very much worse); improvement in CGI-C, therefore, is signified by a positive change.

Within-treatment change from baseline to endpoint was significant: ^#p < 0.05; *p < 0.01; **p < 0.001; ***p < 0.0001.

CGI-C, Clinical Global Impression–Change; MADRS, Montgomery-Åsberg Depression Rating Scale; RLAI, risperidone long-acting injectable.